Integration of B cell responses through Toll-like receptors and antigen receptors

Nature Reviews Immunology

Volumn 12, Issue 4, 2012, Pages 282-294

  Rawlings, David J ^a,b   Schwartz, Marc A ^a,b   Jackson, Shaun W ^a,b   Meyer Bahlburg, Almut ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; APRIL PROTEIN; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; B CELL MATURATION ANTIGEN; BRUTON TYROSINE KINASE; CASPASE RECRUITMENT DOMAIN SIGNALING PROTEIN; FINGOLIMOD; I KAPPA B KINASE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; INTERFERON REGULATORY FACTOR 5; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 10; INTERLEUKIN 6; JANUS KINASE; LOW DENSITY LIPOPROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; MYELOID DIFFERENTIATION FACTOR 88; SPHINGOSINE 1 PHOSPHATE RECEPTOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; UNINDEXED DRUG;

ADAPTIVE IMMUNITY; AGAMMAGLOBULINEMIA; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BACTEREMIA; CELL DIFFERENTIATION; CELL MIGRATION; CELL SELECTION; CELLULAR DISTRIBUTION; DOWN REGULATION; DOWNSTREAM PROCESSING; GENETIC ASSOCIATION; HEALTH PROGRAM; HOMEOSTASIS; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOGLOBULIN DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; INFECTION SENSITIVITY; INNATE IMMUNITY; LUPUS LIKE SYNDROME; NONHUMAN; PHENOTYPE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; REVIEW; SALMONELLA ENTERICA; SALMONELLA TYPHIMURIUM; SIGNAL TRANSDUCTION; STREPTOCOCCUS PNEUMONIAE; T LYMPHOCYTE ACTIVATION; WISKOTT ALDRICH SYNDROME;

ANIMALS; B-LYMPHOCYTES; HUMANS; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84858796247     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri3190     Document Type: Review

References (127)

1. Gavin, A. L. et al. Adjuvant-enhanced antibody responses in the absence of Toll-like receptor signaling. Science 314, 1936-1938 (2006). (Pubitemid 46026117)
2. Isnardi, I. et al. IRAK-4-and MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans. Immunity 29, 746-757 (2008).
3. Meyer-Bahlburg, A., Bandaranayake, A. D., Andrews, S. F. & Rawlings, D. J. Reduced c-myc expression levels limit follicular mature B cell cycling in response to TLR signals. J. Immunol. 182, 4065-4075 (2009).
4. Gururajan, M., Jacob, J. & Pulendran, B. Toll-like receptor expression and responsiveness of distinct murine splenic and mucosal B-cell subsets. PLoS ONE 2, e863 (2007).
5. O'Neill, L. A. J. & Bowie, A. G. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nature Rev. Immunol. 7, 353-364 (2007). (Pubitemid 46674493)
6. Mackay, F. & Schneider, P. Cracking the BAFF code. Nature Rev. Immunol. 9, 491-502 (2009).
7. Katsenelson, N. et al. Synthetic CpG oligodeoxynucleotides augment BAFF-and APRIL-mediated immunoglobulin secretion. Eur. J. Immunol. 37, 1785-1795 (2007). (Pubitemid 47065118)
8. Treml, L. S. et al. TLR stimulation modifies BLyS receptor expression in follicular and marginal zone B cells. J. Immunol. 178, 7531-7539 (2007). (Pubitemid 46898021)
9. Ng, L. G. et al. BAFF costimulation of Toll-like receptor-activated B-1 cells. Eur. J. Immunol. 36, 1837-1846 (2006). (Pubitemid 44089050)
10. Martin, F., Oliver, A. M. & Kearney, J. F. Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens. Immunity 14, 617-629 (2001). (Pubitemid 32520872)
11. This is one of the first reports to clearly delineate the unique function of B-1 and marginal zone B cells in T-independent immune responses.
12. Haas, K. M., Poe, J. C., Steeber, D. A. & Tedder, T. F. B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae. Immunity 23, 7-18 (2005). (Pubitemid 41019653)
13. Van der Hilst, J. C., Smits, B. W. & van der Meer, J. W. Hypogammaglobulinaemia: cumulative experience in 49 patients in a tertiary care institution. Neth. J. Med. 60, 140-147 (2002). (Pubitemid 39089291)
14. Rijkers, G. T., Sanders, L. A. & Zegers, B. J. Anti-capsular polysaccharide antibody deficiency states. Immunodeficiency 5, 1-21 (1993).
15. Kruetzmann, S. et al. Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J. Exp. Med. 197, 939-945 (2003). (Pubitemid 36437871)
16. Genestier, L. et al. TLR agonists selectively promote terminal plasma cell differentiation of B cell subsets specialized in thymus-independent responses. J. Immunol. 178, 7779-7786 (2007). (Pubitemid 46898049)
17. Meyer-Bahlburg, A., Khim, S. & Rawlings, D. J. B cell intrinsic TLR signals amplify but are not required for humoral immunity. J. Exp. Med. 204, 3095-3101 (2007).
18. This study, together with reference 1, demonstrates that multiple protein immunization strategies can efficiently elicit specific antibody responses in the absence of MYD88 expression in B cells.
19. Oliver, A. M., Martin, F., Gartland, G. L., Carter, R. H. & Kearney, J. F. Marginal zone B cells exhibit unique activation, proliferative and immunoglobulin secretory responses. Eur. J. Immunol. 27, 2366-2374 (1997). (Pubitemid 27404323)
20. Oliver, A. M., Martin, F. & Kearney, J. F. IgMhighCD21high lymphocytes enriched in the splenic marginal zone generate effector cells more rapidly than the bulk of follicular B cells. J. Immunol. 162, 7198-7207 (1999). (Pubitemid 29277691)
21. Sindhava, V., Woodman, M. E., Stevenson, B. & Bondada, S. Interleukin-10 mediated autoregulation of murine B-1 B-cells and its role in Borrelia hermsii infection. PLoS ONE 5, e11445 (2010).
22. Blair, P. A. et al. Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. J. Immunol. 182, 3492-3502 (2009).
23. Alugupalli, K. R., Akira, S., Lien, E. & Leong, J. M. MyD88-and Bruton's tyrosine kinase-mediated signals are essential for T cell-independent pathogen-specific IgM responses. J. Immunol. 178, 3740-3749 (2007). (Pubitemid 46417642)
24. Barr, T. A, Brown, S., Mastroeni, P. & Gray, D. B cell intrinsic MyD88 signals drive IFN-γ production from T cells and control switching to IgG2c. J. Immunol. 183, 1005-1012 (2009).
25. Neves, P. et al. Signaling via the MyD88 adaptor protein in B cells suppresses protective immunity during Salmonella typhimurium infection. Immunity 33, 777-790 (2010).
26. This study demonstrated that regulatory B cell activity requires B cell-intrinsic MYD88 signalling in mice infected with S. Typhimurium.
27. Groeneveld, P. H., Erich, T. & Kraal, G. In vivo effects of LPS on B lymphocyte subpopulations. Migration of marginal zone-lymphocytes and IgD-blast formation in the mouse spleen. Immunobiology 170, 402-411 (1985). (Pubitemid 16171460)
28. Kraal, G. Cells in the marginal zone of the spleen. Int. Rev. Cytol. 132, 31-74 (1992).
29. Martin, F. & Kearney, J. F. Marginal-zone B cells. Nature Rev. Immunol. 2, 323-335 (2002). (Pubitemid 37328755)
30. Cinamon, G. et al. Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone. Nature Immunol. 5, 713-720 (2004). (Pubitemid 39023303)
31. Rubtsov, A. V. et al. TLR agonists promote marginal zone B cell activation and facilitate T-dependent IgM responses. J. Immunol. 180, 3882-3888 (2008).
32. Ha, S. A. et al. Regulation of B1 cell migration by signals through Toll-like receptors. J. Exp. Med. 203, 2541-2550 (2006).
33. von Bernuth, H. et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 321, 691-696 (2008).
34. Picard, C. et al. Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. Medicine 89, 403-425 (2010).
35. Picard, C. et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 299, 2076-2079 (2003). (Pubitemid 36383736)
36. References 30 and 32 provided the first descriptions of mutations in MYD88 and IRAK4, respectively, in immunodeficient patients.
37. He, B. et al. The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nature Immunol. 11, 836-845 (2010).
38. This study identifies MYD88 as an adaptor molecule involved in TACI-driven NF-κB signalling, thereby providing a role for MYD88 in T-independent class switching.
39. Castigli, E. et al. TACI and BAFF-R mediate isotype switching in B cells. J. Exp. Med. 201, 35-39 (2005). (Pubitemid 40130081)
40. Salzer, U. et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nature Genet. 37, 820-828 (2005). (Pubitemid 41077107)
41. Barr, T. A., Brown, S., Mastroeni, P. & Gray, D. TLR and B cell receptor signals to B cells differentially program primary and memory Th1 responses to Salmonella enterica. J. Immunol. 185, 2783-2789 (2010).
42. Hwang, I.-Y., Park, C., Harrison, K. & Kehrl, J. H. TLR4 signaling augments B lymphocyte migration and overcomes the restriction that limits access to germinal center dark zones. J. Exp. Med. 206, 2641-2657 (2009).
43. Bernasconi, N. L., Traggiai, E. & Lanzavecchia, A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298, 2199-2202 (2002). (Pubitemid 35471246)
44. Ruprecht, C. R. & Lanzavecchia, A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur. J. Immunol. 36, 810-816 (2006).
45. Pasare, C. & Medzhitov, R. Control of B-cell responses by Toll-like receptors. Nature 438, 364-368 (2005). (Pubitemid 41643953)
46. This study examined the antibody response to protein immunizations and concluded that protein-specific, T-dependent B cell immune responses require B cell-intrinsic TLR signalling.
47. Lanzavecchia, A. & Sallusto, F. Toll-like receptors and innate immunity in B-cell activation and antibody responses. Curr. Opin. Immunol. 19, 268-274 (2007). (Pubitemid 46687008)
48. Palm, N. W. & Medzhitov, R. Immunostimulatory activity of haptenated proteins. Proc. Natl Acad. Sci. USA 106, 4782-4787 (2009).
49. Hou, B. et al. Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response. Immunity 34, 375-384 (2011).
50. In this study, the response to TLR ligands in various physical forms was evaluated in mice with a DC-or B cell-specific MYD88 deficiency. MYD88 signals in B cells were essential for optimal antibody responses to virus-like particles.
51. Yang, R. et al. B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88. J. Immunol. 174, 7912-7919 (2005). (Pubitemid 40806301)
52. Jegerlehner, A. et al. TLR9 signaling in B cells determines class switch recombination to IgG2a. J. Immunol. 178, 2415-2420 (2007). (Pubitemid 46233441)
53. Heer, A. K. et al. TLR signaling fine-tunes anti-influenza B cell responses without regulating effector T cell responses. J. Immunol. 178, 2182-2191 (2007). (Pubitemid 46233416)
54. Guay, H. M., Andreyeva, T. A., Garcea, R. L., Welsh, R. M. & Szomolanyi-Tsuda, E. MyD88 is required for the formation of long-term humoral immunity to virus infection. J. Immunol. 178, 5124-5131 (2007). (Pubitemid 46595296)
55. Delgado, M. F. et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nature Med. 15, 34-41 (2009).
56. Becker-Herman, S. et al. WASp-deficient B cells play a critical, cell-intrinsic role in triggering autoimmunity. J. Exp. Med. 208, 2033-2042 (2011).
57. This study demonstrated that WASP-deficient B cells exhibit signalling abnormalities sufficient to promote a cell-intrinsic, MYD88-dependent break in T cell tolerance that triggers lethal humoral autoimmunity.
58. Shlomchik, M. J. Activating systemic autoimmunity: B's, T's, and tolls. Curr. Opin. Immunol. 21, 626-633 (2009).
59. Green, N. M. & Marshak-Rothstein, A. Toll-like receptor driven B cell activation in the induction of systemic autoimmunity. Semin. Immunol. 23, 106-112 (2011).
60. Leadbetter, E. A. et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416, 603-607 (2002). (Pubitemid 34406754)
61. This study provided the first demonstration that dual BCR and TLR signals can markedly promote the activation of self-reactive B cells by uptake of antibody-DNA complexes via a rheumatoid factor-specific BCR.
62. Lau, C. M. et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J. Exp. Med. 202, 1171-1177 (2005). (Pubitemid 41586947)
63. This study was the first to demonstrate that Myd88 deletion is sufficient to prevent humoral autoimmune disease in vivo. Multiple additional studies have confirmed these findings and expanded on the distinct roles for TLR7 versus TLR9 signals in these events.
64. Nickerson, K. M. et al. TLR9 regulates TLR7-and MyD88-dependent autoantibody production and disease in a murine model of lupus. J. Immunol. 184, 1840-1848 (2010).
65. Yasuda, K. et al. Murine dendritic cell type I IFN production induced by human IgG-RNA immune complexes is IFN regulatory factor (IRF)5 and IRF7 dependent and is required for IL-6 production. J. Immunol. 178, 6876-6885 (2007). (Pubitemid 46847413)
66. Groom, J. R. et al. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J. Exp. Med. 204, 1959-1971 (2007). (Pubitemid 47236330)
67. Ehlers, M., Fukuyama, H., McGaha, T. L., Aderem, A. & Ravetch, J. V. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J. Exp. Med. 203, 553-561 (2006).
68. Christensen, S. R. et al. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25, 417-428 (2006). (Pubitemid 44354217)
69. Christensen, S. R. et al. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J. Exp. Med. 202, 321-331 (2005). (Pubitemid 41043827)
70. Santiago-Raber, M.-L. et al. Critical role of TLR7 in the acceleration of systemic lupus erythematosus in TLR9-deficient mice. J. Autoimmun. 34, 339-348 (2010).
71. Zhang, L. et al. Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in common variable immunodeficiency: clinical and immunologic outcomes in heterozygotes. J. Allergy Clin. Immunol. 120, 1178-1185 (2007). (Pubitemid 350047480)
72. Graham, R. R. et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nature Genet. 38, 550-555 (2006).
73. Jacob, C. O. et al. Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc. Natl Acad. Sci. USA 106, 6256-6261 (2009).
74. Graham, R. R. et al. Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nature Genet. 40, 1059-1061 (2008).
75. Han, J. W. et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nature Genet. 41, 1234-1237 (2009).
76. Tavares, R. M. et al. The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity. Immunity 33, 181-191 (2010).
77. Nanda, S. K. et al. Polyubiquitin binding to ABIN1 is required to prevent autoimmunity. J. Exp. Med. 208, 1215-1228 (2011).
78. Shen, N. et al. Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus. Proc. Natl Acad. Sci. USA 107, 15838-15843 (2010).
79. Huang, C. M. et al. Association of Toll-like receptor 9 gene polymorphism in Chinese patients with systemic lupus erythematosus in Taiwan. Rheumatol. Int. 17 Apr 2011 (doi:10.1007/s00296-011-1925-8).
80. Tao, K. et al. Genetic variations of Toll-like receptor 9 predispose to systemic lupus erythematosus in Japanese population. Ann. Rheum. Dis. 66, 905-909 (2007). (Pubitemid 46999791)
81. O'Garra, A. et al. Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10. Int. Immunol. 2, 821-832 (1990). (Pubitemid 20307067)
82. Burdin, N., Pιronne, C., Banchereau, J. & Rousset, F. Epstein-Barr virus transformation induces B lymphocytes to produce human interleukin 10. J. Exp. Med. 177, 295-304 (1993). (Pubitemid 23117079)
83. Evans, J. G. et al. Novel suppressive function of transitional 2 B cells in experimental arthritis. J. Immunol. 178, 7868-7878 (2007). (Pubitemid 46898059)
84. Yanaba, K., Bouaziz, J. D., Matsushita, T., Tsubata, T. & Tedder, T. F. The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J. Immunol. 182, 7459-7472 (2009).
85. Mizoguchi, A., Mizoguchi, E., Takedatsu, H., Blumberg, R. S. & Bhan, A. K. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 16, 219-230 (2002). (Pubitemid 34211962)
86. Mauri, C. & Ehrenstein, M. R. The "short" history of regulatory B cells. Trends Immunol. 29, 34-40 (2008).
87. Tian, J. et al. Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J. Immunol. 167, 1081-1089 (2001). (Pubitemid 32660868)
88. Parekh, V. V. et al. B cells activated by lipopolysaccharide, but not by anti-Ig and anti-CD40 antibody, induce anergy in CD8+ T cells: role of TGFβ1. J. Immunol. 170, 5897-5911 (2003). (Pubitemid 36682569)
89. Fillatreau, S., Sweenie, C. H., McGeachy, M. J., Gray, D. & Anderton, S. M. B cells regulate autoimmunity by provision of IL-10. Nature Immunol. 3, 944-950 (2002). (Pubitemid 35154008)
90. Ronet, C. et al. Regulatory B cells shape the development of Th2 immune responses in BALB/c mice infected with Leishmania major through IL-10 production. J. Immunol. 184, 886-894 (2010).
91. Hernandez, H. J., Wang, Y. & Stadecker, M. J. In infection with Schistosoma mansoni, B cells are required for T helper type 2 cell responses but not for granuloma formation. J. Immunol. 158, 4832-4837 (1997). (Pubitemid 127483804)
92. Gillan, V., Lawrence, R. A. & Devaney, E. B cells play a regulatory role in mice infected with the L3 of Brugia pahangi. Int. Immunol. 17, 373-382 (2005). (Pubitemid 40568112)
93. Sayi, A. et al. TLR-2-activated B cells suppress Helicobacter-induced preneoplastic gastric immunopathology by inducing T regulatory-1 cells. J. Immunol. 186, 878-890 (2011).
94. Lenert, P., Brummel, R., Field, E. H. & Ashman, R. F. TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production. J. Clin. Immunol. 25, 29-40 (2005). (Pubitemid 40386176)
95. Lampropoulou, V. et al. TLR-activated B cells suppress T cell-mediated autoimmunity. J. Immunol. 180, 4763-4773 (2008).
96. Iwata, Y. et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 117, 530-541 (2011).
97. Blair, P. A. et al. CD19+CD24hiCD38hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 32, 129-140 (2010).
98. Staudt, L. M. Oncogenic activation of NF-κB. Cold Spring Harb. Perspect. Biol. 2, a000109 (2010).
99. Davis, R. E., Brown, K. D., Siebenlist, U. & Staudt, L. M. Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 194, 1861-1874 (2001). (Pubitemid 34028664)
100. Rawlings, D. J., Sommer, K. & Moreno-García, M. E. The CARMA1 signalosome links the signalling machinery of adaptive and innate immunity in lymphocytes. Nature Rev. Immunol. 6, 799-812 (2006). (Pubitemid 44631649)
101. Sommer, K. et al. Phosphorylation of the CARMA1 linker controls NF-κB activation. Immunity 23, 561-574 (2005). (Pubitemid 41779479)
102. Ngo, V. N. et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441, 106-110 (2006).
103. Lenz, G. et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319, 1676-1679 (2008). (Pubitemid 351432507)
104. Davis, R. E. et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463, 88-92 (2010).
105. Ngo, V. N. et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 470, 115-119 (2011).
106. This study identified activating mutations in MYD88 in poor-prognosis human B cell lymphomas and showed that many such tumours also have activating mutations in genes associated with the BCR signalling cascade.
107. Lam, L. T. et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma. Blood 111, 3701-3713 (2008).
108. Ding, B. B. et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 111, 1515-1523 (2008). (Pubitemid 351213441)
109. Puente, X. S. et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475, 101-105 (2011).
110. Michelsen, K. S. et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl Acad. Sci. USA 101, 10679-10684 (2004). (Pubitemid 38955802)
111. Bjorkbacka, H. et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nature Med. 10, 416-421 (2004). (Pubitemid 38508522)
112. Kiechl, S. et al. Toll-like receptor 4 polymorphisms and atherogenesis. N. Engl. J. Med. 347, 185-192 (2002). (Pubitemid 34764822)
113. Lewis, M. J. et al. Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 120, 417-426 (2009).
114. Caligiuri, G., Nicoletti, A., Poirier, B. & Hansson, G. K. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J. Clin. Invest. 109, 745-753 (2002). (Pubitemid 34263151)
115. Zhao, M. et al. FcγRIIB inhibits the development of atherosclerosis in low-density lipoprotein receptor-deficient mice. J. Immunol. 184, 2253-2260 (2010).
116. Kyaw, T. et al. Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis. J. Immunol. 185, 4410-4419 (2010).
117. Ait-Oufella, H. et al. B cell depletion reduces the development of atherosclerosis in mice. J. Exp. Med. 207, 1579-1587 (2010).
118. Bernatsky, S. et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 54, 2550-2557 (2006). (Pubitemid 44205016)
119. Svenungsson, E. et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104, 1887-1893 (2001). (Pubitemid 32983229)
120. Bendelac, A., Bonneville, M. & Kearney, J. F. Autoreactivity by design: innate B and T lymphocytes. Nature Rev. Immunol. 1, 177-186 (2001). (Pubitemid 33741955)
121. Godin, I. E., Garcia-Porrero, J. A., Coutinho, A., Dieterlen-Lievre, F. & Marcos, M. A. Para-aortic splanchnopleura from early mouse embryos contains B1a cell progenitors. Nature 364, 67-70 (1993). (Pubitemid 23233457)
122. Montecino-Rodriguez, E., Leathers, H. & Dorshkind, K. Identification of a B-1 B cell-specified progenitor. Nature Immunol. 7, 293-301 (2006).
123. Griffin, D. O., Holodick, N. E. & Rothstein, T. L. Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+CD27+CD43+CD70-. J. Exp. Med. 208, 67-80 (2011).
124. Ehrenstein, M. R. & Notley, C. A. The importance of natural IgM: scavenger, protector and regulator. Nature Rev. Immunol. 10, 778-786 (2010).
125. Casrouge, A. et al. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science 314, 308-312 (2006). (Pubitemid 44571977)
126. Zhang, S. Y. et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science 317, 1522-1527 (2007).
127. Shlomchik, M. J. Sites and stages of autoreactive B cell activation and regulation. Immunity 28, 18-28 (2008).